zepbound semaglutide or tirzepatide vs Trial Results Evernorth Benefit Option Will Cap

These broad-spectrum agents depend on prompt absorption for adequate tissue penetration, making them less reliable choices during active semaglutide therapy unless administered intravenously

Analysis of protein profiling studies of beta-thalassemia/Hb E disease

N.AntolasicE

GLP-1 Story Continues Here are the key figures since Q2 2024: Q2 2024: GLP-1 revenue: $12 million Total revenue: $325 million Share of GLP-1 revenue: 4 % Q3 2024: GLP-1 revenue: $55 million* Total revenue: $441 million Share of GLP-1 revenue: 12 % Q4 2024: GLP-1 revenue: $162 million* Total revenue: $488 million Share of GLP-1 revenue: 33 % Q1 2025: GLP-1 revenue: $ 230 million Total revenue: $596 million Share of GLP-1 revenue: 39 % Q2 2025: GLP-1 revenue: $190 million Total revenue: $545 million Share of GLP-1 revenue: 35 % * Estimate based on the $229M GLP-1 revenue for FY 2024 Revenue Momentum Stalls Amid GLP-1 Reliance Historically Hims has issued conservative guidance and then surpassed the top end of its range

Kojic acid and arbutin offer excellent alternatives to harsh bleaching agents

Key Takeaways Peptides are short chains of amino acids that act as signaling molecules, directing your cells to repair, regulate, and regenerate